No Weight Gain Among Elderly Schizophrenia Patients After 1 Year of Risperidone Treatment
J Clin Psychiatry 2002;63(2):117-119
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Weight gain has been reported in
younger patients treated with most atypical neuroleptics. The
goal of this study was to examine whether elderly schizophrenic
patients gain weight while being treated with risperidone.
Method: Data are from an international
multicenter, open-label study of 180 elderly (69 men, 111 women),
chronically ill, psychotic patients (meeting DSM-III-R criteria
for schizophrenia or schizophreniform disorder; median age = 72
years [range, 54-89 years]), 97 of whom completed the 12-month
study. At endpoint, the mean dose of risperidone was 3.7 mg/day.
Patients were weighed at baseline and at endpoint.
Results: There was no significant weight gain in
patients who completed the trial (N = 96) or in those who did not
complete the entire trial (N = 31).
Conclusion: The results suggest that risperidone
treatment is not associated with weight gain among elderly
persons with chronic psychosis.